期刊文献+

儿童NS糖皮质激素治疗与25羟基维生素D3的关系 被引量:3

The relationship between glucocorticoid therapy and 25 hydroxyvitamin D in children with nephrotic syndrome
下载PDF
导出
摘要 肾病综合征(NS)是儿童泌尿系统疾病中常见的慢性疾病,目前糖皮质激素是治疗儿童NS免疫抑制剂中的首选用药。长期、大量应用糖皮质激素对于正处在生长发育阶段的儿童有很大的影响,近年来,激素的副作用已引起临床儿科工作者的重视。25羟基维生素D3[25-(OH)D3]是调节骨代谢的主要激素。该文对糖皮质激素在治疗儿童NS过程中与25-(OH)D3的关系进行综述。 Nephrotic syndrome(NS) is a common chronic disease of urinary system in children.Glucocorticoids are currently the preferred drug in the treatment of NS immunosuppressive agents in children.Long-term and massive use of glucocorticoids has a great impact on children at the stage of growth and development.In recent years,the side effects of hormone therapy have attracted the attention of clinical pediatricians.25 hydroxyvitamin D3 [25(OH)D3] is the main hormone that regulates bone metabolism.This article reviews the relationship between glucocorticoids and 25(OH)D3 in the treatment of NS children.
作者 易鸣 黄燕萍 YI Ming;HUANG Yanping(Department of Pediatrics,the First Af filiated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China;Department of Pediatrics,the County Hospital of Jingyang,Shaanxi Xianyang 713700,China)
出处 《中国妇幼健康研究》 2020年第9期1151-1154,共4页 Chinese Journal of Woman and Child Health Research
关键词 肾病综合征 糖皮质激素 25羟基维生素D3 骨代谢 nephrotic syndrome glucocorticoid 25-hydroxyvitamin D3 bone metabolism calcium
  • 相关文献

参考文献1

二级参考文献22

  • 1Donatti TL, Koch VH, Takayama L, et al .Effects of glu- cocorticoids on growth and bone mineralization [J ]. J Pediatr, 2011,87(1) :4-12.
  • 2Feber J,Gaboury I, Ni A, et al .Skeletal findings in children recently initiating glueocortieoids for the treatment of ne- phrotic syndrome[J].Osteoporos Int, 2012,23(2) : 751-760.
  • 3Koran C, Ayar G, Orbak Z.Effects of steroid treatment on bone mineral metabolism in children with glucocorticoid-sen- sitive nephrotic syndrome[J]. West Indian IVied J, 2012,61 (6) :627-630.
  • 4Sbrocchi AM,Rauch F,Matzinger M , et al .Vertebral frac- tures despite normal spine bone mineral density in a boy with nephrotic syndrome[J]. Pediatr Nephrol, 2011,26(1) : 139- 142.
  • 5Wasilewska A, Rybi-SA, Zoch-ZW. Serum RANKL, osteo- protegerin (OPG), and RANKL/OPG ratio in nephrotic children[J]. Pedlatr Ne~hrol, 2010,25(10) :2067-2075.
  • 6Choudhary S, Agarwal I,Mandalam S. Seshadri.Calcium and vitamin Dfor osteoprotection in children with new-onset ne- phrotie syndrome treated with steroids: a prospective, ran- domized, controlled, interventional study [ J ]. Pediatr Nephrol, 2014,29(6) :1025-1032.
  • 7Gamal B.Serum Osteoprotegerin (OPG) in Children with Pri- mary Nephrotic Syndrome [J ]. Saudi J Kidney Dis Transpl, 2011,22(5) : 955-962.
  • 8Vieteria Z,Coehenski Borba, Nddila Ceeyn Pietszkowski Ma as.The use of PTH in the treatment of osteoporosis[J]. Arq Bras Endocrinol Metab, 2010,54(2):213-219.
  • 9Munns CF, Cowell CT.Prevention and treatment of osteopo- rosis in chronically ill ehildren[J]. J Musculoskelet Neuronal Interact, 2005,5 (3) : 262-272.
  • 10Cosman F. Parathyroid hormone treatment for osteoporosis [J]. Curr Opin Endocrinol Diabetes Obes, 2008 , 15(6) 495-501.

共引文献4

同被引文献34

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部